Biotech Values

[jbog]

I bought Impax for all the wrong reasons early this year. I thought they were going to flourish because of their substitute Epi-Pen which never really got off the ground when Mylan came out with their own generic.

What I did learn from Impax was that being a smaller generic you could win market share from the big boys (Teva, Mylan) by keeping your costs low.

Now they want to be big.